TCRCure Biopharma Ltd. is a leading international company focused on streamlined biotechnology development including high throughput antigen-specific TCR cloning, industry-scale virus production, T cell genetic engineering, and immune cell manufacturing.
TCRCure has HQ and a large-scale GMP facility in Guangzhou, China, with additional small-scale GMP capacity in Los Angeles, California and Chongqing, China. In addition, TCRCure has three research and development centers in Los Angeles,
Durham, and Chongqing.
So far, TCRCure has over 100 employees, with more than 40% of them being Ph.Ds. The company has several pipelines of TCR/CAR-T cell therapy products for solid tumors including cervical cancer, nasopharyngeal carcinoma, lung squamous carcinoma, ovarian cancer, endometrial cancer, and brain cancer. TCRCure has started clinical trials with top hospitals around the world.
In addition, TCRCure has solid clinical data and robust pipelines for viral vector and T cell manufacturing. The company has obtained technology authorization, commissioned R&D contracts, received production orders from pharmaceutical companies, and has attracted millions of USD in funding from top investment companies.